Thuc Ly

Thuc Ly

Auto-generated profile, based on publicly available information

Thuc Ly

Department of Otolaryngology‐Head and Neck Surgery University of Kansas Medical Center Kansas City Kansas USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KWKellen Wright
Kellen Wright
TLThuc Ly
Thuc Ly
MKMatthew Kriet
Matthew Kriet
ACAndras Czirok
Andras Czirok
STSufi Mary Thomas
Sufi Mary Thomas
Cancer cells rely on the tumor microenvironment (TME), a composite of non-malignant cells, and extracellular matrix (ECM), for survival, growth, and metastasis. The ECM contributes to the biomechanical properties of the surrounding tissue, in addition to providing signals for tissue development. Cancer-associated fibroblasts (CAFs) are stromal cells in the TME that are integral to cancer progression. Subtypes of CAFs across a variety of cancers have been revealed, and each play a different role in cancer progression or suppression. CAFs secrete signaling molecules and remodel the surrounding ECM by depositing its constituents as well as degrading enzymes. In cancer, a remodeled ECM can lead to tumor-promoting effects. Not only does the remodeled ECM promote growth and allow for easier metastasis, but it can also modulate the immune system. A better understanding of how CAFs remodel the ECM will likely yield novel therapeutic targets. In this review, we summarize the key factors secreted by CAFs that facilitate tumor progression, ECM remodeling, and immune suppression.

31 July 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JHJeff Hirst
Jeff Hirst
HPHarsh B. Pathak
Harsh B. Pathak
SHStephen Hyter
Stephen Hyter
ZPZiyan Y. Pessetto
Ziyan Y. Pessetto
TLThuc Ly
Thuc Ly
AGAndrew Godwin
Andrew Godwin
Drug development for first-line treatment of epithelial ovarian cancer (EOC) has been stagnant for almost three decades. Traditional cell culture methods for primary drug screening do not always accurately reflect clinical disease. To overcome this barrier, we grew a panel of EOC cell lines in three-dimensional (3D) cell cultures to form multicellular tumor spheroids (MCTS). We characterized these MCTS for molecular and cellular features of EOC and performed a comparative screen with cells grown using two-dimensional (2D) cell culture to identify previously unappreciated anticancer drugs. MCTS exhibited greater resistance to chemotherapeutic agents, showed signs of senescence and hypoxia, and expressed a number of stem cell–associated transcripts including ALDH1A and CD133, also known as PROM1. Using a library of clinically repurposed drugs, we identified candidates with preferential activity in MCTS over 2D cultured cells. One of the lead compounds, the dual COX/LOX inhibitor licofelone, reversed the stem-like properties of ovarian MCTS. Licofelone also synergized with paclitaxel in ovarian MCTS models and in a patient-derived tumor xenograft model. Importantly, the combination of licofelone with paclitaxel prolonged the median survival of mice (>141 days) relative to paclitaxel (115 days), licofelone (37 days), or vehicle (30 days). Increased efficacy was confirmed by Mantel–Haenszel HR compared with vehicle (HR = 0.037) and paclitaxel (HR = 0.017). These results identify for the first time an unappreciated, anti-inflammatory drug that can reverse chemotherapeutic resistance in ovarian cancer, highlighting the need to clinically evaluate licofelone in combination with first-line chemotherapy in primary and chemotherapy-refractory EOC. Significance: This study highlights the use of an in vitro spheroid 3D drug screening model to identify new therapeutic approaches to reverse chemotherapy resistance in ovarian cancer. Cancer Res; 78(15); 4370–85. ©2018 AACR.

1 September 2020 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
TLThuc Ly
Thuc Ly
SHSitaram Harihar
Sitaram Harihar
DWDanny R. Welch
Danny R. Welch

22 February 2020 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
SHSitaram Harihar
Sitaram Harihar
SRSrijit Ray
Srijit Ray
SNSamyukta Narayanan
Samyukta Narayanan
ASAnirudh Santhoshkumar
Anirudh Santhoshkumar
TLThuc Ly
Thuc Ly
DWDanny R. Welch
Danny R. Welch

31 October 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
LALevi Arnold
Levi Arnold
JGJuan Pineda Gomez
Juan Pineda Gomez
MBMichael Barry
Michael Barry
MYMarrion Yap
Marrion Yap
LJLaura Jackson
Laura Jackson
STSufi Mary Thomas
Sufi Mary Thomas
Aim: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a survival rate below fifty percent. Addressing meager therapeutic options, a series of small m

21 April 2025 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
TLThuc Ly
Thuc Ly
AGAthena E. Golfinos‐Owens
Athena E. Golfinos‐Owens
NRNaren Raja
Naren Raja
LALevi Arnold
Levi Arnold
PAPachiappan Arjunan
Pachiappan Arjunan
STSufi Mary Thomas
Sufi Mary Thomas